NIKI net incomeFY2025-$1.36M
NIKI net income was -$1.36M for fiscal 2025 (ended Dec 31, 2025), compared with -$4.27M in fiscal 2024.
Niki BioSolutions Inc. (NIKI) financials
For fiscal 2025 (ended Dec 31, 2025), Niki BioSolutions Inc. reported -$1.36M of net income.
- Net income, FY2025
- -$1.36M
- EPS, diluted, FY2025
- -$0.19
- Cash
- $3.45M
- Market cap
- $4.8M
FY2021FY2023
FY2018FY2025
FY2018FY2023
NIKI revenue and earnings growth
NIKI EPSFY2025-$0.19
NIKI diluted EPS was -$0.19 for fiscal 2025 (ended Dec 31, 2025), compared with -$0.78 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $431.4K | $1.30M | $1.54M | - | - | - |
| Cost of revenue | - | - | $420.8K | $1.22M | $1.46M | - | - | - |
| Gross profit | - | - | $10.6K | $80.1K | $81.9K | - | - | - |
| Research and development | $352.9K | $2.20M | $5.20M | $9.22M | $10.87M | $11.59M | $6.94M | $3.10M |
| Selling, general and admin | $573.1K | $669.5K | $1.93M | $5.22M | $5.41M | $4.85M | $7.37M | $4.92M |
| Pre-tax income | -$1.38M | -$4.16M | -$4.34M | - | - | - | - | - |
| Net income | -$1.36M | -$4.27M | -$2.82M | -$9.80M | -$25.05M | $4.92M | -$20.12M | -$14.83M |
| EPS, basic | -$0.19 | -$0.78 | -$0.62 | -$2.75 | -$7.15 | $2.03 | -$6.40 | -$5.30 |
| EPS, diluted | -$0.19 | -$0.78 | -$0.62 | -$2.75 | -$7.15 | $2.00 | -$6.40 | -$5.30 |
| Diluted shares | 7.4M | 5.5M | 4.5M | 3.6M | 3.5M | 3.2M | 2.9M | 2.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.45M | $874.2K | $2.01M | $5.01M | $8.26M | $3.63M | $5.29M | $26.11M |
| Short-term investments | - | - | - | $102.5K | $236.6K | - | $1.06M | $1.01M |
| Receivables | - | - | $47.7K | $174.4K | $78.7K | $62.2K | $40.5K | $2.8K |
| Inventory | - | - | - | $27.7K | $35.8K | $39.1K | $34.2K | $30.6K |
| Current assets | $3.59M | $959.6K | $2.48M | $7.07M | $12.69M | $33.66M | $8.03M | $28.72M |
| Total assets | $18.69M | $16.13M | $20.64M | $20.87M | $21.91M | $44.23M | $23.95M | $45.07M |
| Current liabilities | $4.59M | $4.34M | $2.10M | $12.50M | $4.38M | $3.87M | $2.67M | $12.18M |
| Long-term debt | - | - | - | $129.8K | $296.2K | $296.2K | $294.6K | $3.42M |
| Total debt | - | - | - | $129.8K | $296.2K | $296.2K | $294.6K | $3.42M |
| Total liabilities | $4.90M | $4.35M | $5.26M | $13.03M | $4.40M | $6.08M | $9.10M | $12.33M |
| Shareholders' equity | $23.12M | $21.13M | $15.38M | $7.83M | $17.51M | $38.15M | $14.85M | $32.75M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.84M | -$1.19M | -$7.72M | -$12.32M | -$14.65M | -$15.93M | -$13.38M | -$10.04M |
| Capital expenditures | - | - | $3.0K | $186.9K | $131.8K | $161.3K | $837.1K | $5.65M |
| Free cash flow | - | - | -$7.73M | -$12.51M | -$14.78M | -$16.09M | -$14.22M | -$15.68M |
| Investing cash flow | - | $58.6K | $624.8K | $2.44M | $16.51M | $1.84M | -$108.1K | -$6.06M |
| Financing cash flow | $4.42M | - | $4.09M | $6.63M | $2.78M | $12.42M | -$7.32M | $25.48M |
| Stock-based compensation | - | - | $1.27M | $1.65M | $1.68M | $1.48M | $1.61M | - |
| Depreciation and amortization | - | $255.0K | $1.13M | $1.21M | $1.19M | $1.33M | $1.30M | $682.3K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | -66.7% | -15.9% | - | - | - | - |
| Gross margin | - | - | 2.4% | 6.2% | 5.3% | - | - | - |
| Net margin | - | - | -654.8% | -756.2% | -1624.6% | - | - | - |
| Free cash flow margin | - | - | -1791.3% | -965.0% | -958.9% | - | - | - |
| Return on equity | -5.9% | -20.2% | -18.4% | -125.1% | -143.1% | 12.9% | -135.5% | -45.3% |
| Return on assets | -7.3% | -26.5% | -13.7% | -47.0% | -114.3% | 11.1% | -84.0% | -32.9% |
| Current ratio | 0.78 | 0.22 | 1.18 | 0.57 | 2.90 | 8.70 | 3.00 | 2.36 |
| Debt to equity | - | - | - | 0.02 | 0.02 | 0.01 | 0.02 | 0.10 |
Source: XBRL data Niki BioSolutions Inc. files with the SEC, latest filing dated Mar 27, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Apr 28, 2023.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
NIKI peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NIKI | - | - | -$1.36M | - | $4.8M |
| ASML | €32.67B | +15.6% | €9.61B | 29.4% | $576.26B |
| LRCX | $26.13B | +33.4% | $8.45B | 32.3% | $282.21B |
| TMO | $47.35B | +8.3% | $7.07B | 14.9% | $259.44B |
| DE | $47.98B | +8.0% | $4.87B | 10.2% | $181.60B |
| DHR | $25.61B | +5.5% | $4.33B | 16.9% | $163.93B |
| ETN | $31.98B | +20.1% | $3.90B | 12.2% | $137.13B |
| JCI | $25.67B | +8.8% | $2.85B | 11.1% | $83.63B |
| ITW | $16.65B | +4.8% | $3.23B | 19.4% | $81.71B |
NIKI FAQ
5 questionsIs NIKI profitable?
No. Niki BioSolutions Inc. reported a net loss of $1.36M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does NIKI have?
Niki BioSolutions Inc. reported $3.45M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is NIKI earnings per share?
Diluted earnings per share were -$0.19 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did NIKI last report financial results?
The latest statements here come from Niki BioSolutions Inc.'s 20-F filed on Mar 27, 2026, covering the period ended Dec 31, 2025.Where does this NIKI financial data come from?
Quantisnow builds these statements from the structured XBRL data Niki BioSolutions Inc. files with the SEC. It is provided for information only and is not investment advice.